Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies

Biomedical and Life Sciences

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. / Foulds, Penny; Yokota, O; Thurston, A et al.
In: Neurobiology of Disease, Vol. 45, No. 1, 01.2012, p. 188-195.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Foulds, P, Yokota, O, Thurston, A, Davidson, Y, Ahmed, Z, Holton, J, Thompson, JC, Akiyama, H, Arai, T, Hasegawa, M, Gerhard, A, Allsop, D & Mann, DMA 2012, 'Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies', Neurobiology of Disease, vol. 45, no. 1, pp. 188-195. https://doi.org/10.1016/j.nbd.2011.08.003

APA

Foulds, P., Yokota, O., Thurston, A., Davidson, Y., Ahmed, Z., Holton, J., Thompson, J. C., Akiyama, H., Arai, T., Hasegawa, M., Gerhard, A., Allsop, D., & Mann, D. M. A. (2012). Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiology of Disease, 45(1), 188-195. https://doi.org/10.1016/j.nbd.2011.08.003

Vancouver

Foulds P, Yokota O, Thurston A, Davidson Y, Ahmed Z, Holton J et al. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiology of Disease. 2012 Jan;45(1):188-195. doi: 10.1016/j.nbd.2011.08.003

Author

Foulds, Penny ; Yokota, O ; Thurston, A et al. / Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. In: Neurobiology of Disease. 2012 ; Vol. 45, No. 1. pp. 188-195.

Bibtex

@article{71844be55fef4c16b8a2170532057b2e,

title = "Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies",

abstract = "Differentiating clinically between Parkinson's disease (PD) and the atypical parkinsonian syndromes of Progressive supranuclear palsy (PSP), corticobasal syndrome (CBS) and multiple system atrophy (MSA) is challenging but crucial for patient management and recruitment into clinical trials. Because PD (and the related disorder Dementia with Lewy bodies (DLB)) and MSA are characterised by the deposition of aggregated forms of α-synuclein protein (α-syn) in the brain, whereas CBS and PSP are tauopathies, we have developed immunoassays to detect levels of total and oligomeric forms of α-syn, and phosphorylated and phosphorylated oligomeric forms of α-syn, within body fluids, in an attempt to find a biomarker that will differentiate between these disorders. Levels of these 4 different forms of α-syn were measured in post mortem samples of ventricular cerebrospinal fluid (CSF) obtained from 76 patients with PD, DLB, PSP or MSA, and in 20 healthy controls. Mean CSF levels of total and oligomeric α-syn, and phosphorylated α-syn, did not vary significantly between the diagnostic groups, whereas mean CSF levels of phosphorylated oligomeric α-syn did differ significantly (p",

keywords = "Parkinson's disease, Dementia with Lewy Bodies, Multiple system atrophy, Alpha synuclein , Cerebrospinal fluid",

author = "Penny Foulds and O Yokota and A Thurston and Y Davidson and Z Ahmed and J Holton and Thompson, {J C} and H Akiyama and T Arai and M Hasegawa and A Gerhard and David Allsop and Mann, {D M A}",

year = "2012",

month = jan,

doi = "10.1016/j.nbd.2011.08.003",

language = "English",

volume = "45",

pages = "188--195",

journal = "Neurobiology of Disease",

issn = "1095-953X",

publisher = "ACADEMIC PRESS INC ELSEVIER SCIENCE",

number = "1",

}

RIS

TY - JOUR

T1 - Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies

AU - Foulds, Penny

AU - Yokota, O

AU - Thurston, A

AU - Davidson, Y

AU - Ahmed, Z

AU - Holton, J

AU - Thompson, J C

AU - Akiyama, H

AU - Arai, T

AU - Hasegawa, M

AU - Gerhard, A

AU - Allsop, David

AU - Mann, D M A

PY - 2012/1

Y1 - 2012/1

N2 - Differentiating clinically between Parkinson's disease (PD) and the atypical parkinsonian syndromes of Progressive supranuclear palsy (PSP), corticobasal syndrome (CBS) and multiple system atrophy (MSA) is challenging but crucial for patient management and recruitment into clinical trials. Because PD (and the related disorder Dementia with Lewy bodies (DLB)) and MSA are characterised by the deposition of aggregated forms of α-synuclein protein (α-syn) in the brain, whereas CBS and PSP are tauopathies, we have developed immunoassays to detect levels of total and oligomeric forms of α-syn, and phosphorylated and phosphorylated oligomeric forms of α-syn, within body fluids, in an attempt to find a biomarker that will differentiate between these disorders. Levels of these 4 different forms of α-syn were measured in post mortem samples of ventricular cerebrospinal fluid (CSF) obtained from 76 patients with PD, DLB, PSP or MSA, and in 20 healthy controls. Mean CSF levels of total and oligomeric α-syn, and phosphorylated α-syn, did not vary significantly between the diagnostic groups, whereas mean CSF levels of phosphorylated oligomeric α-syn did differ significantly (p

AB - Differentiating clinically between Parkinson's disease (PD) and the atypical parkinsonian syndromes of Progressive supranuclear palsy (PSP), corticobasal syndrome (CBS) and multiple system atrophy (MSA) is challenging but crucial for patient management and recruitment into clinical trials. Because PD (and the related disorder Dementia with Lewy bodies (DLB)) and MSA are characterised by the deposition of aggregated forms of α-synuclein protein (α-syn) in the brain, whereas CBS and PSP are tauopathies, we have developed immunoassays to detect levels of total and oligomeric forms of α-syn, and phosphorylated and phosphorylated oligomeric forms of α-syn, within body fluids, in an attempt to find a biomarker that will differentiate between these disorders. Levels of these 4 different forms of α-syn were measured in post mortem samples of ventricular cerebrospinal fluid (CSF) obtained from 76 patients with PD, DLB, PSP or MSA, and in 20 healthy controls. Mean CSF levels of total and oligomeric α-syn, and phosphorylated α-syn, did not vary significantly between the diagnostic groups, whereas mean CSF levels of phosphorylated oligomeric α-syn did differ significantly (p

KW - Parkinson's disease

KW - Dementia with Lewy Bodies

KW - Multiple system atrophy

KW - Alpha synuclein

KW - Cerebrospinal fluid

U2 - 10.1016/j.nbd.2011.08.003

DO - 10.1016/j.nbd.2011.08.003

M3 - Journal article

C2 - 21856424

VL - 45

SP - 188

EP - 195

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 1095-953X

IS - 1

ER -

Research

Associated organisational unit

Links

Text available via DOI:

Keywords